Stocktoria
Tonix Pharmaceuticals Holding Corp. TNXP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-03-29
Tonix Pharmaceuticals Holding Corp. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | — | — |
| R&D expense | $44.5M | $40.0M | $86.7M | $81.9M | $68.8M |
| SG&A expense | $87.7M | $40.1M | $34.8M | $30.2M | — |
| Operating income | -$125.7M | -$136.7M | -$118.4M | -$112.1M | -$92.3M |
| Net income | -$124.0M | -$130.0M | -$116.7M | -$110.2M | -$92.3M |
| EPS (diluted) | $-14.57 | $-176.60 | $-14720.25 | $-20.01 | $-8.10 |
| Operating cash flow | -$99.8M | -$60.9M | -$102.0M | -$98.1M | -$75.6M |
| Free cash flow | -$103.2M | -$61.0M | -$109.9M | -$146.2M | -$110.9M |
| Cash & equivalents | $207.6M | $98.8M | $24.9M | $120.2M | $178.7M |
| Inventory | — | $8.4M | $13.6M | — | — |
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M |
| Total liabilities | $32.0M | $23.3M | $48.9M | $18.5M | $22.2M |
| Shareholders' equity | $245.2M | $139.6M | $105.5M | $207.2M | $218.7M |
Source: SEC EDGAR filings · CIK 0001430306 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.